clidinium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
muscarinic receptors agonists/antagonists	676	7020-55-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clidinium clidinium bromide quarzan	a synthetic anticholinergic agent that has antispasmodic and antisecretory effect on the gastrointestinal tract Molecular weight: 352.45 Formula: C22H26NO3 CLOGP: -0.05 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 46.53 ALOGS: -6.01 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clidinium
clidinium bromide
quarzan

a synthetic anticholinergic agent that has antispasmodic and antisecretory effect on the gastrointestinal tract

Molecular weight: 352.45
Formula: C22H26NO3
CLOGP: -0.05
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 46.53
ALOGS: -6.01
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
None	FDA	ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Apraxia	60.18	28.05	12	1018	1809	63486183
Perseveration	51.97	28.05	8	1022	267	63487725
Disorientation	49.66	28.05	20	1010	39432	63448560
Hyperreflexia	41.28	28.05	11	1019	5923	63482069
Cognitive disorder	36.86	28.05	18	1012	55797	63432195
Myoclonus	34.43	28.05	12	1018	15856	63472136
Dementia	28.80	28.05	11	1019	18783	63469209

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Apraxia	59.78	31.68	12	839	2855	79740682
Perseveration	52.39	31.68	8	843	389	79743148
Hyperreflexia	42.09	31.68	11	840	8374	79735163
Disorientation	38.80	31.68	17	834	62759	79680778
Cognitive disorder	37.04	31.68	17	834	69909	79673628
Myoclonus	32.84	31.68	12	839	27648	79715889

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A03CA02	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS Synthetic anticholinergic agents in combination with psycholeptics
FDA PE	N0000008779	Decreased Parasympathetic Acetylcholine Activity
FDA PE	N0000009022	Digestive/GI System Activity Alteration
FDA PE	N0000009048	GI Motility Alteration
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
CHEBI has role	CHEBI:38070	antiarrhythmic agent
CHEBI has role	CHEBI:50370	parasympatholytics
CHEBI has role	CHEBI:53784	antispasmodics
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Irritable bowel syndrome	indication	10743008	DOID:9778
Enterocolitis	indication	43752006
Brain damage	contraindication	2470005
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Urinary tract obstruction	contraindication	7163005	DOID:5200
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of lung	contraindication	19829001	DOID:850
Glaucoma	contraindication	23986001	DOID:1686
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Hyperthyroidism	contraindication	34486009	DOID:7998
Depressive disorder	contraindication	35489007
Hypertensive disorder	contraindication	38341003	DOID:10763
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Hyperactive behavior	contraindication	44548000
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Ulcerative colitis	contraindication	64766004	DOID:8577
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Sleep apnea	contraindication	73430006	DOID:0050847
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Hiatal hernia	contraindication	84089009	DOID:12642
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Hypoalbuminemia	contraindication	119247004
Gastrointestinal obstruction	contraindication	126765001
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Drowsy	contraindication	271782001
Pregnancy, function	contraindication	289908002
Severe chronic obstructive pulmonary disease	contraindication	313299006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Porphyria	contraindication	418470004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.67	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST				CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	9.60		IUPHAR	CHEMBL

External reference:

ID	Source
4019682	VUID
N0000179084	NUI
D00716	KEGG_DRUG
3485-62-9	SECONDARY_CAS_RN
21232	RXNORM
4018831	VANDF
4019682	VANDF
C0055877	UMLSCUI
CHEBI:3743	CHEBI
CHEMBL620	ChEMBL_ID
DB00771	DRUGBANK_ID
CHEMBL1200950	ChEMBL_ID
C054940	MESH_SUPPLEMENTAL_RECORD_UI
2784	PUBCHEM_CID
366	IUPHAR_LIGAND_ID
BO76JF850N	UNII
3953	MMSL
4465	MMSL
d00991	MMSL
001747	NDDF
004702	NDDF
387323005	SNOMEDCT_US
57853003	SNOMEDCT_US
87283008	SNOMEDCT_US
463	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Librax	HUMAN PRESCRIPTION DRUG LABEL	2	0187-4100	CAPSULE	2.50 mg	ORAL	NDA	18 sections
Librax	HUMAN PRESCRIPTION DRUG LABEL	2	0187-4100	CAPSULE	2.50 mg	ORAL	NDA	18 sections
Not applicable	HUMAN PRESCRIPTION DRUG LABEL	2	0276-0500	CAPSULE	2.50 1	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	10135-622	CAPSULE	2.50 mg	ORAL	UNAPPROVED DRUG OTHER	17 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	11534-197	CAPSULE	2.50 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	11534-197	CAPSULE	2.50 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	11534-197	CAPSULE	2.50 mg	ORAL	ANDA	19 sections
chlordiazepoxide hydrochloride and clidinium bromide	HUMAN PRESCRIPTION DRUG LABEL	2	23155-808	CAPSULE	2.50 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	42494-409	CAPSULE	2.50 mg	ORAL	NDA authorized generic	20 sections
CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	2	42571-381	CAPSULE	2.50 mg	ORAL	ANDA	22 sections
CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	2	42571-381	CAPSULE	2.50 mg	ORAL	ANDA	22 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	42582-300	CAPSULE	2.50 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	42582-301	CAPSULE	2.50 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	43598-706	CAPSULE	2.50 mg	ORAL	ANDA	15 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	43598-706	CAPSULE	2.50 mg	ORAL	ANDA	15 sections
Chlordiazepoxide Hydrochloride/Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	50090-0131	CAPSULE	2.50 mg	ORAL	Unapproved drug other	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	50090-1528	CAPSULE	2.50 mg	ORAL	NDA authorized generic	18 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	50090-6310	CAPSULE	2.50 mg	ORAL	ANDA	15 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	51293-607	CAPSULE	2.50 mg	ORAL	UNAPPROVED DRUG OTHER	18 sections
Chlordiazepoxide Hydrochloride/Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	51293-696	CAPSULE	2.50 mg	ORAL	ANDA	20 sections
Chlordiazepoxide Hydrochloride/Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	51293-696	CAPSULE	2.50 mg	ORAL	ANDA	20 sections
chlordiazepoxide hydrochloride and clidinium bromide	HUMAN PRESCRIPTION DRUG LABEL	2	60219-1677	CAPSULE	2.50 mg	ORAL	ANDA	19 sections
chlordiazepoxide hydrochloride and clidinium bromide	HUMAN PRESCRIPTION DRUG LABEL	2	60219-1677	CAPSULE	2.50 mg	ORAL	ANDA	19 sections
chlordiazepoxide hydrochloride and clidinium bromide	HUMAN PRESCRIPTION DRUG LABEL	2	60219-1677	CAPSULE	2.50 mg	ORAL	ANDA	19 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	60687-639	CAPSULE	2.50 mg	ORAL	ANDA	21 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	60687-639	CAPSULE	2.50 mg	ORAL	ANDA	21 sections
Chlordiazepoxide Hydrochloride and Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	60687-639	CAPSULE	2.50 mg	ORAL	ANDA	21 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	2	62135-696	CAPSULE	2.50 mg	ORAL	ANDA	15 sections
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE	HUMAN PRESCRIPTION DRUG LABEL	2	62135-696	CAPSULE	2.50 mg	ORAL	ANDA	15 sections
Chlordiazepoxide Hydrochloride/Clidinium Bromide	HUMAN PRESCRIPTION DRUG LABEL	2	63629-2021	CAPSULE	2.50 mg	ORAL	ANDA	19 sections